Exagen Inc. (XGN) shares soared 29.4% in the last trading session to close at $5.02. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and ...

We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's ...

Exagen Inc. (XGN) shares soared 5.5% in the last trading session to close at $7.32. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...

Virtu Financial LLC acquired a new stake in shares of Exagen Inc. (NASDAQ:XGN – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 11,203 ...

CEO John Aballi highlighted several important developments, including the successful integration of new biomarkers into the AVISE CTD test. He noted that these biomarkers have driven a $90 incremental ...